Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor
Authors:
- Lucio N. GordanLGLucio N. Gordan
- David RayDRDavid Ray
- Stephen C. IjiomaSIStephen C. Ijioma
- George DranitsarisGeorge Dranitsaris
- Amanda WarnerAWAmanda Warner
- Trevor HeritageTHTrevor Heritage
- Matthew FinkMFMatthew Fink
- David WenkDWDavid Wenk
- Paul ChadwickPCPaul Chadwick
- Natasha KhrystolubovaNKNatasha Khrystolubova
- Shachar PelesSPShachar Peles
Open Access
- 14 January 2024
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 31 (1) , 501-510
Abstract
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education. We investigated the impact of a BP program in patients with relapsed/refractory multiple myeloma (RRMM) receiving selinexor. Features of the BP program that were specific to selinexor were initiating selinexor at doses ≤80 mg once weekly and the upfront use of standardized antiemetics. Study endpoints included time to treatment failure (TTF), duration of therapy, dose limiting toxicities and overall survival. Comparative analysis on TTF and duration of therapy was conducted using a log-rank test and multivariate Cox proportional hazard regression. Over the ensuing 12-month post-BP period, 41 patients received selinexor-based therapy compared to 68 patients who received selinexor-based therapy pre-BP implementation. Patients treated in the post-BP period had reductions in TTF (hazard ratio [HR] = 0.50; 95% CI: 0.27 to 0.92). Patients in the pre-BP period were four times more likely to stop therapy than those in the post-period (odds ratio [OR] = 4.0, 95% CI: 1.75 to 9.3). The findings suggest a BP program tailored to selinexor could increase the time to treatment failure, increase treatment duration and lower the incidence of drug limiting toxicities.Keywords
Funding Information
- Karyopharm Therapeutics Inc.
This publication has 10 references indexed in Scilit:
- Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston StudyBlood, 2021
- Current and emerging immunotherapeutic approaches to the treatment of multiple myelomaTherapeutic Advances in Hematology, 2019
- Multiple myeloma clonal evolution in homogeneously treated patients.Leukemia, 2018
- Addressing unmeasured confounding in comparative observational researchPharmacoepidemiology and Drug Safety, 2018
- The HITECH Era in RetrospectNew England Journal of Medicine, 2017
- Sensitivity Analysis in Observational Research: Introducing the E-ValueAnnals of Internal Medicine, 2017
- Epigenetic strategies to reverse drug resistance in heterogeneous multiple myelomaClinical Epigenetics, 2017
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsLeukemia, 2013
- Clonal competition with alternating dominance in multiple myelomaBlood, 2012
- The Triple Aim: Care, Health, And CostHealth Affairs, 2008